Envista (NYSE:NVST) Price Target Raised to $22.00 at Jefferies Financial Group

Envista (NYSE:NVST) had its target price increased by Jefferies Financial Group from $20.00 to $22.00 in a report issued on Thursday morning,Benzinga reports. They currently have a hold rating on the stock.

Several other equities research analysts also recently commented on the company. Piper Sandler boosted their price objective on Envista from $16.00 to $17.00 and gave the company a “neutral” rating in a report on Thursday, October 31st. Leerink Partners raised Envista from an “underperform” rating to a “market perform” rating and increased their price target for the company from $16.00 to $23.00 in a research report on Thursday, October 31st. Wells Fargo & Company began coverage on shares of Envista in a report on Tuesday, October 8th. They set an “equal weight” rating and a $20.00 price objective on the stock. Leerink Partnrs upgraded shares of Envista from a “strong sell” rating to a “hold” rating in a report on Thursday, October 31st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Envista in a research note on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $20.13.

Envista Trading Up 1.1 %

Shares of NVST stock opened at $21.28 on Thursday. The company has a quick ratio of 1.77, a current ratio of 2.08 and a debt-to-equity ratio of 0.42. Envista has a 52 week low of $15.15 and a 52 week high of $24.79. The firm has a 50 day moving average of $19.99 and a 200-day moving average of $18.78.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.03. The firm had revenue of $601.00 million during the quarter, compared to the consensus estimate of $590.34 million. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The business’s revenue was down 4.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 earnings per share. Sell-side analysts predict that Envista will post 0.72 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Sei Investments Co. raised its stake in Envista by 20.4% in the 2nd quarter. Sei Investments Co. now owns 925,170 shares of the company’s stock valued at $15,386,000 after acquiring an additional 157,048 shares during the period. Pacer Advisors Inc. raised its position in shares of Envista by 22.2% in the third quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company’s stock valued at $69,749,000 after purchasing an additional 642,401 shares during the period. Diamond Hill Capital Management Inc. lifted its stake in shares of Envista by 8.1% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 1,335,710 shares of the company’s stock valued at $26,394,000 after buying an additional 100,360 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of Envista by 138.5% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 404,589 shares of the company’s stock valued at $7,995,000 after buying an additional 234,941 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Envista by 45.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,474,064 shares of the company’s stock worth $24,484,000 after buying an additional 459,167 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.